scholarly journals eIF2α integrates proteotoxic signals both from ER and cytoplasm: Hsp70-Bag3 module regulates HRI-dependent phosphorylation of eIF2α

2021 ◽  
Author(s):  
Shivani Patel ◽  
Santosh Kumar ◽  
Arkadi Hesin ◽  
Julia Yaglom ◽  
Michael Y. Sherman

The major heat shock protein Hsp70 has been implicated in many stages of cancer development. These effects are mediated by a scaffold protein Bag3 that binds to Hsp70 and links it to components of multiple cancer-related signaling pathways. Accordingly, the Hsp70-Bag3 complex has been targeted by small molecules, which showed strong anti-cancer effects. Here, our initial question was how JG-98, an allosteric inhibitor of Hsp70 that blocks its interaction with Bag3, causes cell death. Breast epithelial cells MCF10A transformed with a single oncogene Her2 showed higher sensitivity to JG-98 then parental MCF10A cells. RNA expression analysis showed that this enhanced sensitivity correlated with higher induction of the UPR genes. Indeed, depletion of the pro-apoptotic UPR responsive transcription factor CHOP significantly protected cells from JG-98. Surprisingly, only the eIF2α-associated branch of the UPR was activated by JG-98, suggesting that the response was not related to the ER proteotoxicity. Indeed, it was dependent on activation of a distinct cytoplasmic eIF2α kinase HRI. HRI-dependent phosphorylation of eIF2α was also activated by the cytoplasmic proteotoxicity via Hsp70-Bag3 complex, which directly associates with HRI. Dissociation of Hsp70-Bag3 complex led to Bag3-dependent degradation of HRI via autophagy. Therefore, eIF2α integrates proteotoxicity signals from both ER and cytoplasm, and the cytoplasmic response mediates cytotoxicity of the Hsp70-Bag3 inhibitors.

2021 ◽  
Vol 22 ◽  
Author(s):  
M İhsan Han ◽  
Ş. Güniz Küçükgüzel

: Spreading rapidly in recent years, cancer has become the cause of one of the highest mortality rates after cardiovascular diseases. The reason for cancer development is still not clearly understood despite enormous research activities in this area. Scientists are now working on the biology of cancer, especially on the root cause of cancer development. The aim is to treat the cancer disease, and thus cure the patients. The continuing efforts on the development of novel molecules as potential anti-cancer agents are essential for this purpose. The main aim of this review was to present a survey on the medicinal chemistry of thioethers and to provide practical data on their cytotoxicities against various cancer cell lines. The research articles published between 2001-2020 were consulted in the preparation of this review article, though patent literature was not included here. The thioether-containing heterocyclic compounds may emerge as a new class of potent and effective anti-cancer agents soon.


Author(s):  
Lajos Gera ◽  
Daniel C. Chan ◽  
Laimute Taraseviciene-Stewart ◽  
Vitalija Simkeviciene ◽  
Paul A. Bunn ◽  
...  

Medicina ◽  
2019 ◽  
Vol 55 (8) ◽  
pp. 414 ◽  
Author(s):  
Crisci ◽  
Amitrano ◽  
Saggese ◽  
Muto ◽  
Sarno ◽  
...  

The upgraded knowledge of tumor biology and microenviroment provides information on differences in neoplastic and normal cells. Thus, the need to target these differences led to the development of novel molecules (targeted therapy) active against the neoplastic cells’ inner workings. There are several types of targeted agents, including Small Molecules Inhibitors (SMIs), monoclonal antibodies (mAbs), interfering RNA (iRNA) molecules and microRNA. In the clinical practice, these new medicines generate a multilayered step in pharmacokinetics (PK), which encompasses a broad individual PK variability, and unpredictable outcomes according to the pharmacogenetics (PG) profile of the patient (e.g., cytochrome P450 enzyme), and to patient characteristics such as adherence to treatment and environmental factors. This review focuses on the use of targeted agents in-human phase I/II/III clinical trials in cancer-hematology. Thus, it outlines the up-to-date anticancer drugs suitable for targeted therapies and the most recent finding in pharmacogenomics related to drug response. Besides, a summary assessment of the genotyping costs has been discussed. Targeted therapy seems to be an effective and less toxic therapeutic approach in onco-hematology. The identification of individual PG profile should be a new resource for oncologists to make treatment decisions for the patients to minimize the toxicity and or inefficacy of therapy. This could allow the clinicians to evaluate benefits and restrictions, regarding costs and applicability, of the most suitable pharmacological approach for performing a tailor-made therapy.


2019 ◽  
Vol 9 (1) ◽  
Author(s):  
Praachi B. Jain ◽  
Patrícia S. Guerreiro ◽  
Sara Canato ◽  
Florence Janody

AbstractAberrant expression of the Spectraplakin Dystonin (DST) has been observed in various cancers, including those of the breast. However, little is known about its role in carcinogenesis. In this report, we demonstrate that Dystonin is a candidate tumour suppressor in breast cancer and provide an underlying molecular mechanism. We show that in MCF10A cells, Dystonin is necessary to restrain cell growth, anchorage-independent growth, self-renewal properties and resistance to doxorubicin. Strikingly, while Dystonin maintains focal adhesion integrity, promotes cell spreading and cell-substratum adhesion, it prevents Zyxin accumulation, stabilizes LATS and restricts YAP activation. Moreover, treating DST-depleted MCF10A cells with the YAP inhibitor Verteporfin prevents their growth. In vivo, the Drosophila Dystonin Short stop also restricts tissue growth by limiting Yorkie activity. As the two Dystonin isoforms BPAG1eA and BPAG1e are necessary to inhibit the acquisition of transformed features and are both downregulated in breast tumour samples and in MCF10A cells with conditional induction of the Src proto-oncogene, they could function as the predominant Dystonin tumour suppressor variants in breast epithelial cells. Thus, their loss could deem as promising prognostic biomarkers for breast cancer.


TECHNOLOGY ◽  
2013 ◽  
Vol 01 (01) ◽  
pp. 58-62 ◽  
Author(s):  
Gareth P. Keeley ◽  
Arlene O'Neill ◽  
Michael Holzinger ◽  
Serge Cosnier ◽  
Jonathan N. Coleman ◽  
...  

The electrochemical detection of hydrogen peroxide, H 2 O 2, and hydrazine, N 2 H 4, is of considerable interest because of the serious health risks associated with these compounds. The unique zeolite structure of Prussian blue, Fe 4[ Fe ( CN )6]3, endows it with excellent catalytic activity towards these small molecules, but its immobilisation on suitable support materials is limited by its solubility at neutral and basic pH values. Here we report an electroanalytical sensor for peroxide and hydrazine based on composites of Prussian blue and graphene nano-sheets (GNSs). The latter are fabricated using the liquid-phase exfoliation of graphite. When immobilised on graphene, Prussian blue is shown to exhibit higher sensitivity towards these analytes than a number of commercially available graphitic supports, including edge-plane pyrolytic graphite (EPPG) electrodes. The incorporation of graphene into electode systems could lead to great advances in sensor technology for these and many other species of interest.


2020 ◽  
Vol 56 (34) ◽  
pp. 4672-4675 ◽  
Author(s):  
Alexander R. Nödling ◽  
Emily M. Mills ◽  
Xuefei Li ◽  
Davide Cardella ◽  
Edward J. Sayers ◽  
...  

Conjugation of small molecules to a simple cyanine dye can lead to organelle-specific delivery.


2021 ◽  
Vol 22 (9) ◽  
pp. 4320
Author(s):  
Benjamin Caulier ◽  
Jorrit M. Enserink ◽  
Sébastien Wälchli

Chimeric antigen receptor (CAR) therapy is a promising modality for the treatment of advanced cancers that are otherwise incurable. During the last decade, different centers worldwide have tested the anti-CD19 CAR T cells and shown clinical benefits in the treatment of B cell tumors. However, despite these encouraging results, CAR treatment has also been found to lead to serious side effects and capricious response profiles in patients. In addition, the CD19 CAR success has been difficult to reproduce for other types of malignancy. The appearance of resistant tumor variants, the lack of antigen specificity, and the occurrence of severe adverse effects due to over-stimulation of the therapeutic cells have been identified as the major impediments. This has motivated a growing interest in developing strategies to overcome these hurdles through CAR control. Among them, the combination of small molecules and approved drugs with CAR T cells has been investigated. These have been exploited to induce a synergistic anti-cancer effect but also to control the presence of the CAR T cells or tune the therapeutic activity. In the present review, we discuss opportunistic and rational approaches involving drugs featuring anti-cancer efficacy and CAR-adjustable effect.


MedChemComm ◽  
2017 ◽  
Vol 8 (2) ◽  
pp. 268-275
Author(s):  
Haixiang Pei ◽  
Yunqi Li ◽  
Mingyao Liu ◽  
Yihua Chen

Twist, as one of the important embryonic transcription factors, regulates epithelial–mesenchymal transition (EMT) and migration in embryo formation and cancer development.


Sign in / Sign up

Export Citation Format

Share Document